Filtered By:
Condition: Bleeding
Countries: Japan Health
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 236 results found since Jan 2013.
One-year outcomes of the pivotal clinical trial of a balloon-expandable transcatheter aortic valve implantation in Japanese dialysis patients
CONCLUSIONS: TAVR using SAPIEN 3 is safe and effective for the treatment of Japanese dialysis patients with symptomatic severe aortic valve stenosis.PMID:34348863 | DOI:10.1016/j.jjcc.2021.07.006
Source: Journal of Cardiology - August 5, 2021 Category: Cardiology Authors: Koichi Maeda Toru Kuratani Isamu Mizote Kentaro Hayashida Hikaru Tsuruta Tatsuo Takahashi Keiichi Fukuda Hideyuki Shimizu Yasushi Sakata Yoshiki Sawa Source Type: research
Bleeding Outcomes After Percutaneous Coronary Intervention in the Past Two Decades in Japan - From the CREDO-Kyoto Registry Cohort-2 and Cohort-3
CONCLUSIONS: In this historical comparative study, Cohort-3 compared with Cohort-2 was associated with excess bleeding risk, which might be at least partly explained by the difference in P2Y12receptor blockers.PMID:34526432 | DOI:10.1253/circj.CJ-21-0526
Source: Circulation Journal - September 16, 2021 Category: Cardiology Authors: Masahiro Natsuaki Takeshi Morimoto Hiroki Shiomi Ko Yamamoto Kyohei Yamaji Hirotoshi Watanabe Takashi Uegaito Mitsuo Matsuda Toshihiro Tamura Ryoji Taniguchi Moriaki Inoko Hiroshi Mabuchi Teruki Takeda Takenori Domei Manabu Shirotani Natsuhiko Ehara Hiros Source Type: research
Impact of PARIS and CREDO-Kyoto Thrombotic and Bleeding Risk Scores on Clinical Outcomes in Patients With Acute Myocardial Infarction
CONCLUSIONS: In the present Japanese cohort of acute MI patients undergoing contemporary primary PCI, the PARIS and CREDO-Kyoto thrombotic and bleeding risk scores were discriminative for predicting ischemic and bleeding events.PMID:34588393 | DOI:10.1253/circj.CJ-21-0556
Source: Circulation Journal - September 30, 2021 Category: Cardiology Authors: Daichi Yamashita Yuichi Saito Takanori Sato Tadahiro Matsumoto Kan Saito Shinichi Wakabayashi Hideki Kitahara Koichi Sano Yoshio Kobayashi Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Impact of mitral versus aortic bioprosthetic valve position on thromboembolism and bleeding risk in patients with atrial fibrillation
CONCLUSIONS: In Japanese patients with AF and bioprosthetic valves, thromboembolic risk does not differ on the basis of valve position. Bleeding risk is higher in patients with MV bioprostheses, although valve position itself might not be an independent predictor for bleeding.PMID:34716054 | DOI:10.1016/j.jjcc.2021.10.002
Source: Journal of Cardiology - October 30, 2021 Category: Cardiology Authors: Yuki Obayashi Makoto Miyake Masashi Amano Takeshi Kitai Misa Takegami Kunihiro Nishimura Toshihiro Tamura Yutaka Furukawa Chisato Izumi Source Type: research
